Feedback
We would very much appreciate any thoughts you may have about OpenCME and how it could be made more useful for physicians like you.
We would very much appreciate any thoughts you may have about OpenCME and how it could be made more useful for physicians like you.
Only 1 class of glucose-lowering agents—sodium-glucose cotransporter 2 (SGLT2) inhibitors—has been reported to decrease the risk of cardiovascular events primarily by reducing the risk of the development or progression of heart failure. In a landmark trial called Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes [EMPA-REG Outcomes], long-term treatment with empagliflozin prevented fatal and nonfatal heart failure events but did not reduce the risk of myocardial infarction or stroke in diabetic patients.
Credit Types: | CME |
Credit Amount: | 1.00 Credits |
Release Date: | 2017-Sep-20 |
Expiration Date: | 2020-Sep-20 |
Estimated Time for Completion: | 1 hour |
Registration Required: | Yes |
Cost: | $30.00 |
Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.
Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.